Diabetes management in the real world and the impact of adherence to guideline recommendations

Abstract

Objective:

To evaluate diabetes management in the real world, examining adherence to the American Diabetic Association (ADA) guidelines on frequency of glycated hemoglobin A1c (A1C) testing and antidiabetic treatment modifications in patients with type 2 diabetes and measuring the impact of adherence to the guidelines for achieving an A1C target <7%.

Research design and methods:

Retrospective analyses of claims data were conducted in three groups of patients aged ≥18 years with at least two diagnoses of type 2 diabetes in a large US health insurance claims database between January 2009 and December 2011 and with A1C ≥7% (≥53 mmol/mol). Descriptive analyses were performed on adherence to A1C testing frequency and adherence to antidiabetic treatment modification. Pearson’s chi-square test and logistic regression were conducted to estimate the odds ratios.

Results:

Of 42,837 patients evaluated for adherence to the ADA guideline for A1C testing frequency, only 7% were fully adherent for 1 year. Analysis of 95,330 patients for adherence to antidiabetic treatment modification revealed that drug therapy was modified in accordance with ADA guidelines for 39% of patients. Among 1337 treatment-naive patients meeting the selection criteria, only 3% met both testing frequency and treatment modification guidelines; the odds of achieving the A1C target of <7% were approximately five-fold higher in patients who met both guidelines versus those who did not (odds ratio 5.29; P < 0.0001).

Conclusions:

This study, based on real-world data from a large type 2 diabetes patient population, demonstrated that adherence to ADA guidelines for A1C testing frequency and drug treatment modifications was extremely low. Achievement of glycemic control (A1C <7%) was significantly associated with adherence to both A1C testing frequency and antidiabetic treatment modification guidelines. Limitations of this study include the retrospective nature, lack of important patient clinical information, and issues with incomplete source data.

Keywords::

• Adherence to guidelines
• Antidiabetic treatment
• Patient outcome assessment
• Type 2 diabetes mellitus
• Treatment modification

Transparency

Declaration of funding

The study was funded by Novo Nordisk Inc.

The authors were responsible for conducting the research, analyzing the data, extensively editing each draft of the manuscript, and approving the submission of the final draft.

Declaration of financial/other relationships

J.L. has disclosed that she is an employee of Novo Nordisk Inc., and holds no stock in the company. Y.L. has disclosed that he is an employee of Kelly Services, sponsored by Novo Nordisk Inc.

CMRO peer reviewers on this manuscript have received an honorarium from CMRO for their review work, but have no relevant financial or other relationships to disclose.

Acknowledgments

Medical writing and editorial support was provided by Craig Albright, PhD, and Roderick Sayce, BSc, MBA, at Complete Publication Solutions, LLC; this support was funded by Novo Nordisk. The authors thank Paula Smith, Lisa Chen, and Aman Matharoo at Novo Nordisk for their editorial assistance, as well as Jennell Palaia and Bill Matthews for their assistance with conducting literature searches.

Previous presentation: Preliminary versions of the research described in this manuscript were presented in abstract form at the 73rd Scientific Session of the American Diabetes Association, 21–25 June 2013, Chicago, IL, USA; and at the ISPOR 18th Annual International Meeting, 18–22 May 2013, New Orleans, LA, USA.